Regulating Immune Responses Induced by PEGylated Messenger RNA-Lipid Nanoparticle Vaccine

Area of Science:

• Immunology
• Vaccinology
• Nanotechnology

Background:

• Messenger RNA (mRNA)-based therapeutics and vaccines have advanced disease treatment and prevention.
• Lipid nanoparticles (LNPs) are highly effective delivery vehicles for mRNA.
• mRNA can activate innate immunity through pattern recognition receptors (PRRs), influencing vaccine responses.

Purpose of the Study:

• To summarize the mechanisms of innate immunity induced by mRNA.
• To discuss adverse reactions associated with polyethylene glycol (PEG) in mRNA-LNP vaccines, including accelerated blood clearance (ABC) and anaphylaxis.
• To review strategies for mitigating PEG-induced immune responses and enhancing vaccine safety.

Main Methods:

• Literature review of studies on mRNA-LNP vaccines, innate immunity, and PEG-related adverse reactions.
• Analysis of mechanisms underlying PEG-induced hypersensitivity and complement activation.
• Examination of approaches to modify or replace PEG and induce immune tolerance.

Main Results:

• mRNA can trigger innate immune responses via PRRs, leading to inflammatory cytokine production.
• PEGylation of LNPs enhances stability but can cause adverse reactions like ABC and anaphylaxis.
• Modifying or replacing PEG, and inducing immune tolerance, are promising strategies to reduce vaccine-associated hypersensitivity.

Conclusions:

• Understanding mRNA-induced innate immunity is crucial for vaccine design.
• Addressing PEG-related adverse reactions is essential for developing safe and effective mRNA-LNP vaccines.
• Strategies like PEG modification and immune tolerance induction hold potential for future vaccine development.